Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Joysquare-5 is an oral **small-molecule phosphodiesterase type 5 inhibitor** marketed by Golden Square for **erectile dysfunction** and also described for **benign prostatic hyperplasia**. The product is presented as a **tablet** and appears to be part of Golden Square's branded generic urology portfolio in India. Available context supports a PDE5 inhibitor mechanism that increases cyclic guanosine monophosphate signaling and relaxes penile vascular smooth muscle to facilitate erection with sexual stimulation, but the **exact active ingredient was not explicitly identified** in the provided materials, so the product is best annotated as a branded PDE5 inhibitor medicine of uncertain specific molecule identity.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Joysquare-5.